{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T03:29:35Z","timestamp":1768534175097,"version":"3.49.0"},"reference-count":31,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJTLD Open"],"accepted":{"date-parts":[[2025,7,21]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>SUMMARY<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Early diagnosis of TB with drug susceptibility testing (DST) is critical to achieve successful treatment outcomes. We aimed to develop and test a novel colorimetric, 12-well, thin-layer agar-based test to assess its accuracy for TB diagnosis and DST in a clinical setting in Southern Mozambique.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Development of the first prototype of the second generation (2G) test in the laboratory setting followed by a cross-sectional diagnostic accuracy study with consecutive recruitment of subjects with microbiologically confirmed TB using GeneXpert MTB\/RIF Ultra.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      In the laboratory setting, the 2G test showed 100% accuracy in detecting resistance of genotypically characterised drug-resistant\n                      <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                      strains. In the clinical setting, the sensitivity of the 2G test to detect\n                      <jats:italic>M.tb<\/jats:italic>\n                      complex versus Xpert and Mycobacteria Growth Indicator Tube (MGIT) culture using fresh sputa was 45.9% and 45.2%, respectively. The 2G test sensitivity versus MGIT decreased to 23.1% when using frozen decontaminated sputum samples.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>In the clinical setting, the 2G test showed a low sensitivity versus Xpert and MGIT. The 2G test sensitivity was lower when frozen instead of fresh sputa was used. Despite these results, important information was collected to further improve this 2G test prototype and its implementation in resource-constrained settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5588\/ijtldopen.25.0326","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T04:34:41Z","timestamp":1763008481000},"page":"685-691","source":"Crossref","is-referenced-by-count":0,"title":["Development and evaluation of the phenotypic 2G test to detect drug-resistant TB"],"prefix":"10.5588","volume":"2","author":[{"given":"J.I.","family":"Garcia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.T.","family":"Mambuque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.D.","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Schami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Munguambe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Tembe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Saavedra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.-H.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-M.","family":"Balada-Llasat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.I.","family":"Restrepo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Yotebieng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gelfond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.L.","family":"Garcia-Basteiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.B.","family":"Torrelles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3554","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"key":"2026011502270501000_2.11.685.1","unstructured":"World Health Organization . Implementing the end TB strategy: the essentials. 2022 update. Geneva: WHO, 2022."},{"key":"2026011502270501000_2.11.685.2","doi-asserted-by":"crossref","first-page":"870768","DOI":"10.3389\/fimmu.2022.870768","article-title":"Tuberculosis phenotypic and genotypic drug susceptibility testing and immunodiagnostics: a review","volume":"13","author":"Yusoof","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"2026011502270501000_2.11.685.3","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/0033354917708989","article-title":"Delayed and unreported drug-susceptibility testing results in the US national tuberculosis surveillance system, 1993-2014","volume":"132","author":"Jones","year":"2017","journal-title":"Public Health Rep"},{"issue":"3","key":"2026011502270501000_2.11.685.4","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3201\/eid2003.130951","article-title":"Use of drug-susceptibility testing for management of drug-resistant tuberculosis, Thailand, 2004-2008","volume":"20","author":"Lam","year":"2014","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"2026011502270501000_2.11.685.5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.rppnen.2017.12.002","article-title":"Point of care diagnostics for tuberculosis","volume":"24","author":"Garca-Basteiro","year":"2018","journal-title":"Pulmonology"},{"key":"2026011502270501000_2.11.685.6","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-020-4997-x"},{"key":"2026011502270501000_2.11.685.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033400"},{"key":"2026011502270501000_2.11.685.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117166"},{"key":"2026011502270501000_2.11.685.9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202410-2096ST"},{"issue":"12","key":"2026011502270501000_2.11.685.10","doi-asserted-by":"crossref","first-page":"e972","DOI":"10.1016\/S2666-5247(23)00172-6","article-title":"Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study","volume":"4","author":"Derendinger","year":"2023","journal-title":"Lancet Microbe"},{"issue":"5","key":"2026011502270501000_2.11.685.11","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1093\/cid\/ciaf174","article-title":"Bedaquiline resistance and treatment outcomes among patients With tuberculosis previously exposed to bedaquiline in India: a multicentric retrospective cohort study","volume":"80","author":"Singla","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026011502270501000_2.11.685.12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijid.2020.12.071","article-title":"A successful introduction to a non-expert setting of the thin-layer agar Colour Test as an indirect phenotypic drug susceptibility test for Mycobacterium tuberculosis","volume":"104","author":"Klaos","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"5","key":"2026011502270501000_2.11.685.13","doi-asserted-by":"crossref","first-page":"e0215679","DOI":"10.1371\/journal.pone.0215679","article-title":"Evaluation of the tuberculosis culture color plate test for rapid detection of drug susceptible and drug-resistant Mycobacterium tuberculosis in a resource-limited setting, Addis Ababa, Ethiopia","volume":"14","author":"Mekonnen","year":"2019","journal-title":"PLoS One"},{"key":"2026011502270501000_2.11.685.14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.tube.2018.11.007","article-title":"Accuracy of the color plate micro-colony detection for the diagnosis of Mycobacterium tuberculosis complex in Northwest Ethiopia","volume":"114","author":"Shibabaw","year":"2019","journal-title":"Tuberculosis"},{"key":"2026011502270501000_2.11.685.15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijid.2019.10.041","article-title":"MDR\/XDR-TB colour test for drug susceptibility testing of Mycobacterium tuberculosis, Northwest Ethiopia","volume":"90","author":"Shibabaw","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"8","key":"2026011502270501000_2.11.685.16","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.5588\/ijtld.11.0609","article-title":"The colour test for drug susceptibility testing of Mycobacterium tuberculosis strains","volume":"16","author":"Toit","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"2026011502270501000_2.11.685.17","doi-asserted-by":"crossref","first-page":"690","DOI":"10.4102\/ajlm.v7i1.690","article-title":"Low-cost diagnostic test for susceptible and drug-resistant tuberculosis in rural Malawi","volume":"7","author":"Zhang","year":"2018","journal-title":"Afr J Lab Med"},{"issue":"2","key":"2026011502270501000_2.11.685.18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40471-021-00269-2","article-title":"New developments and insights in the improvement of Mycobacterium tuberculosis vaccines and diagnostics within the end TB strategy","volume":"8","author":"Garc\u00eda","year":"2021","journal-title":"Curr Epidemiol Rep"},{"key":"2026011502270501000_2.11.685.19","unstructured":"World Health Organization . Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. Geneva: WHO, 2018."},{"key":"2026011502270501000_2.11.685.20","unstructured":"World Health Organization . Tuberculosis profile: Mozambique. Geneva: WHO, 2025."},{"key":"2026011502270501000_2.11.685.21","unstructured":"World Health Organization . Mozambique HIV country profile 2024. Geneva: WHO, 2024."},{"key":"2026011502270501000_2.11.685.22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100823"},{"key":"2026011502270501000_2.11.685.23","unstructured":"World Health Organization . Technical report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine). Geneva: WHO, 2021."},{"key":"2026011502270501000_2.11.685.24","unstructured":"Cepheid . Xpert\u00ae MTB\/RIF Ultra. Solna, Sweden: Cepheid, 2023."},{"key":"2026011502270501000_2.11.685.25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012799"},{"key":"2026011502270501000_2.11.685.26","unstructured":"BD Systems . BBL\u2122 middlebrook 7H11\/\/7H11 selective agar. Quality control procedures. Franklin Lakes, NJ, USA: Becton Dickinson and Company, 2012, pp. 1-4."},{"issue":"4","key":"2026011502270501000_2.11.685.27","doi-asserted-by":"crossref","first-page":"182","DOI":"10.6026\/97320630011182","article-title":"Evolution of bacterial and fungal growth media","volume":"11","author":"Basu","year":"2015","journal-title":"Bioinformation"},{"key":"2026011502270501000_2.11.685.28","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00793-8"},{"key":"2026011502270501000_2.11.685.29","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02263-20"},{"issue":"4","key":"2026011502270501000_2.11.685.30","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/cid\/ciad684","article-title":"Monitoring of first-line drug resistance mutations outside the scope of Xpert MTB\/RIF ultra is needed for successful control of DR-TB in Southern Mozambique","volume":"78","author":"Mariner-Llicer","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2026011502270501000_2.11.685.31","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ijmyco.2014.09.006","article-title":"Decontamination of sputum for longer time in sodium hydroxide for isolation of Mycobacterium tuberculosis","volume":"3","author":"Satapathy","year":"2014","journal-title":"Int J Mycobacteriol"}],"container-title":["IJTLD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.5588\/ijtldopen.25.0326","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:27:53Z","timestamp":1768472873000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.theunion.org\/lookup\/doi\/10.5588\/ijtldopen.25.0326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,1]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.5588\/ijtldopen.25.0326"],"URL":"https:\/\/doi.org\/10.5588\/ijtldopen.25.0326","relation":{},"ISSN":["3005-7590"],"issn-type":[{"value":"3005-7590","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}